Alzheon

Framingham, United States Founded: 2013 • Age: 13 yrs
Oral inhibitors of amyloid aggregation for Alzheimers treatment are developed.

About Alzheon

Alzheon is a Healthcare company based in Framingham (United States) founded in 2013. Oral inhibitors of amyloid aggregation for Alzheimers treatment are developed. Alzheon has raised $274.04 million across 13 funding rounds from investors including NIH, HHS and Ally Bridge Group. Alzheon offers products and services including valiltramiprosate and ALZ-801. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is Future X Beta s.r.o. Its competitors include T3D Therapeutics, Longeveron and Totus Medicines; 3 of its 3 listed competitors have raised funding.

Company details

Alzheon was founded in 2013 and is headquartered in Framingham, United States. Focus is placed on the biotechnology sector, specifically the development of oral therapeutics for Alzheimers disease. The lead candidate, ALZ-801, a prodrug of tramiprosate, is advanced as an inhibitor targeting amyloid aggregation and neurotoxicity. Clinical operations are conducted to address key pathological hallmarks of the disease.

  • Headquarters Framingham, United States
  • Sectors
    Healthcare
  • Website alzheon.com
  • Social LinkedIn X
  • Legal Name Future X Beta S.R.O.
Operational Areas
Key Metrics
  • Total Equity Funding
    $274.04M (USD)

    in 13 rounds

  • Latest Funding Round
    $78.8M (USD), Series E

    Aug 2026

  • Investors
    NIH

    & 3 more

Products & Services of Alzheon

Alzheon offers a comprehensive portfolio of products and services, including valiltramiprosate and ALZ-801.

valiltramiprosate
Anti-Amyloid Treatment

Investigational oral drug targeting amyloid oligomers in Alzheimer's disease

ALZ-801
Prodrug Therapy

Oral treatment for early Alzheimer's in APOE4 carriers

Funding Insights of Alzheon

Alzheon has successfully raised a total of $274.04M across 13 strategic funding rounds. The most recent funding activity was a Series E round of $78.8 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $274.04M
  • Total Rounds 13
  • Last Round Series E β€” $78.8M
  • Investors Count 4

Latest 10 of 13 funding rounds of Alzheon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2026$78.8MSeries E––
–
Jun 2024$100MSeries E–Alerce Medical Technology Partners
–
Feb 2024$1MSeries D––
–
Apr 2022$50MSeries D––
–
Sep 2020$2.43MSeries B––
–
Aug 2020Grant––
Aug 2020$51.19MGrant––
Jan 2020$6.16MSeries B––
–
Sep 2018$19.8MSeries B––
–
May 2017$5.3MSeries A––
–
Valuation history

4 investors in total: 4 institutional.

Investors in Alzheon

Alzheon has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Ally Bridge Group.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Private equity and hedge fund investments in healthcare are managed.
ally-bridge.comHong Kong, China
Drug discovery services are provided to the biopharma sector.
1887nih.govUnited States
Public health and human services are overseen by HHS.
1953hhs.gov
Premium access

Investor details for Alzheon

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Alzheon

38 people are tracked at Alzheon (12 in leadership, 25 in board & advisors, 1 in team).

NameRoleGroup
Aidan Power
Chief Development OfficerLeadership
Martin Tolar
Founder, President & CEOLeadership
Kenneth Mace
Chief Financial OfficerLeadership
Susan Abushakra
CMOLeadership
Patrick Kesslak
VP, Clinical Development & Medical AffairsLeadership
Erwan De Naurois
VP, FinanceLeadership
Stacy Trudeau
Senior Director Of FinanceLeadership
Yasemin Khakian
Chief Of StaffLeadership
Luke Tolar
Senior Director, Business DevelopmentLeadership
Earvin Liang
VP, Clinical DevelopmentLeadership
Adem Albayrak
Chief Data OfficerLeadership
Stacey Kaufusi
Vice President, Quality | Head Of QualityLeadership
Diane K. Jorkasky
DirectorBoard & advisors
Jordan Heller
DirectorBoard & advisors
Christopher Noel Dunn
Non Executive DirectorBoard & advisors
Neil Flanzraich
Executive ChairmanBoard & advisors
Kaj Blennow
Scientific AdvisorBoard & advisors
Jakub Hort
Scientific AdvisorBoard & advisors
Serge Gauthier
Scientific AdvisorBoard & advisors
Steven Jacobsen
Scientific AdvisorBoard & advisors

18 more people are available in the full profile.

Premium access

Complete people profiles for Alzheon

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Alzheon

3 dated milestones of Alzheon across 13 years, from founding to its latest funding, stage changes and deals.

  1. Founded Alzheon is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Series E, of $78.8M.

Competitors of Alzheon

Alzheon has 3 listed competitors in our database, 3 of them funded. They include T3D Therapeutics, Longeveron and Totus Medicines.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
t3dtherapeutics.com2013Durham, United States$33.02M
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
longeveron.com2014Miami, United States$1.05M23
Cellular therapies for aging-related and life-threatening conditions are developed.
totusmedicines.com2019Cambridge, United States$106M23
Genome-scale drug discovery platform is provided for treating multiple diseases.
Premium access

Detailed competitors of Alzheon

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Alzheon

The website of Alzheon (alzheon.com) receives about 4.8K visits a month.

  • Monthly visits
    4.8K

    ▼ 2% vs previous month

Similar websites

Websites whose visitors overlap most with Alzheon. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
leqembihcp.com
leqembihcp.com
100%
#2,737,943–

Top companies in Neurology

3 companies that operate in the same segment as Alzheon (Neurology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Developer of therapeutics for psychiatric and neurologic diseases
2002New York, New York, United StatesUSD 80.87 MUSD 250.31 M600
Biologics platform developed for intracellular delivery in rare diseases.
2016Boston, Massachusetts, United StatesUSD 175.25 MUSD 25.42 M183
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Alzheon

Premium access

Complete news archive for Alzheon

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Alzheon

Alzheon was founded in 2013.

Alzheon is headquartered in Framingham, United States. It is registered at Framingham, Massachusetts, United States.

Alzheon is a funded company, having raised a total of $274.04M across 13 funding rounds to date. The company's 1st funding round was a Series A of $5.3M, raised on Oct 2013.

Alzheon was founded in 2013 and is headquartered in Framingham, United States. Focus is placed on the biotechnology sector, specifically the development of oral therapeutics for Alzheimers disease. The lead candidate, ALZ-801, a prodrug of tramiprosate, is advanced as an inhibitor targeting amyloid aggregation and neurotoxicity. Clinical operations are conducted to address key pathological hallmarks of the disease.

Alzheon's top competitors include Longeveron, Totus Medicines and T3D Therapeutics.

Alzheon offers valiltramiprosate and ALZ-801.

Alzheon has 4 investors. Key investors include NIH, HHS, Ally Bridge Group, and Alerce Medical Technology Partners.

Alzheon operates through Future X Beta S.R.O..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available